KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Notes Payables (2024 - 2025)

Esperion Therapeutics' Notes Payables history spans 2 years, with the latest figure at $54.9 million for Q3 2025.

  • For Q3 2025, Notes Payables changed N/A year-over-year to $54.9 million; the TTM value through Sep 2025 reached $54.9 million, changed N/A, while the annual FY2024 figure was $54.6 million, N/A changed from the prior year.
  • Notes Payables reached $54.9 million in Q3 2025 per ESPR's latest filing, roughly flat from $54.8 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $54.9 million in Q3 2025 to a low of $54.6 million in Q4 2024.